Nab-paclitaxel in combination with carboplatin for a previously treated thymic carcinoma

Go Makimoto, Keiichi Fujiwara, Hiromi Watanabe, Nobuhisa Kameyama, Mizuho Matsushita, Kanmei Rai, Ken Sato, Toshiro Yonei, Toshio Sato, Takuo Shibayama

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We present the case of a 40-year-old man with previously treated thymic carcinoma, complaining of gradually worsening back pain. Computed tomography scans of the chest showed multiple pleural disseminated nodules with a pleural effusion in the right thorax. The patient was treated with carboplatin on day 1 plus nab-paclitaxel on day 1 and 8 in cycles repeated every 4 weeks. Objective tumor shrinkage was observed after 4 cycles of this regimen. In addition, the elevated serum cytokeratin 19 fragment level decreased, and the patient's back pain was relieved without any analgesics. Although he experienced grade 4 neutropenia and granulocyte colony-stimulating factor (G-CSF) injection, the severity of thrombocytopenia and nonhematological toxicities such as reversible neuropathy did not exceed grade 1 during the treatment. To our knowledge, this is the first report to demonstrate the efficacy of combination chemotherapy consisting of carboplatin and nab-paclitaxel against thymic carcinoma. This case report suggests that nab-paclitaxel in combination with carboplatin can be a favorable chemotherapy regimen for advanced thymic carcinoma.

Original languageEnglish
Pages (from-to)14-17
Number of pages4
JournalCase Reports in Oncology
Volume7
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Thymoma
Carboplatin
Back Pain
Thorax
Keratin-19
Granulocyte Colony-Stimulating Factor
Pleural Effusion
Combination Drug Therapy
Neutropenia
Thrombocytopenia
Analgesics
Tomography
Drug Therapy
Injections
Serum
130-nm albumin-bound paclitaxel
Neoplasms
Therapeutics

Keywords

  • Carboplatin
  • Chemotherapy
  • nab-Paclitaxel
  • Thymic carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Makimoto, G., Fujiwara, K., Watanabe, H., Kameyama, N., Matsushita, M., Rai, K., ... Shibayama, T. (2014). Nab-paclitaxel in combination with carboplatin for a previously treated thymic carcinoma. Case Reports in Oncology, 7(1), 14-17. https://doi.org/10.1159/000357938

Nab-paclitaxel in combination with carboplatin for a previously treated thymic carcinoma. / Makimoto, Go; Fujiwara, Keiichi; Watanabe, Hiromi; Kameyama, Nobuhisa; Matsushita, Mizuho; Rai, Kanmei; Sato, Ken; Yonei, Toshiro; Sato, Toshio; Shibayama, Takuo.

In: Case Reports in Oncology, Vol. 7, No. 1, 2014, p. 14-17.

Research output: Contribution to journalArticle

Makimoto, G, Fujiwara, K, Watanabe, H, Kameyama, N, Matsushita, M, Rai, K, Sato, K, Yonei, T, Sato, T & Shibayama, T 2014, 'Nab-paclitaxel in combination with carboplatin for a previously treated thymic carcinoma', Case Reports in Oncology, vol. 7, no. 1, pp. 14-17. https://doi.org/10.1159/000357938
Makimoto, Go ; Fujiwara, Keiichi ; Watanabe, Hiromi ; Kameyama, Nobuhisa ; Matsushita, Mizuho ; Rai, Kanmei ; Sato, Ken ; Yonei, Toshiro ; Sato, Toshio ; Shibayama, Takuo. / Nab-paclitaxel in combination with carboplatin for a previously treated thymic carcinoma. In: Case Reports in Oncology. 2014 ; Vol. 7, No. 1. pp. 14-17.
@article{fa3fed78221b4c62b6e6fcf79ea55fc6,
title = "Nab-paclitaxel in combination with carboplatin for a previously treated thymic carcinoma",
abstract = "We present the case of a 40-year-old man with previously treated thymic carcinoma, complaining of gradually worsening back pain. Computed tomography scans of the chest showed multiple pleural disseminated nodules with a pleural effusion in the right thorax. The patient was treated with carboplatin on day 1 plus nab-paclitaxel on day 1 and 8 in cycles repeated every 4 weeks. Objective tumor shrinkage was observed after 4 cycles of this regimen. In addition, the elevated serum cytokeratin 19 fragment level decreased, and the patient's back pain was relieved without any analgesics. Although he experienced grade 4 neutropenia and granulocyte colony-stimulating factor (G-CSF) injection, the severity of thrombocytopenia and nonhematological toxicities such as reversible neuropathy did not exceed grade 1 during the treatment. To our knowledge, this is the first report to demonstrate the efficacy of combination chemotherapy consisting of carboplatin and nab-paclitaxel against thymic carcinoma. This case report suggests that nab-paclitaxel in combination with carboplatin can be a favorable chemotherapy regimen for advanced thymic carcinoma.",
keywords = "Carboplatin, Chemotherapy, nab-Paclitaxel, Thymic carcinoma",
author = "Go Makimoto and Keiichi Fujiwara and Hiromi Watanabe and Nobuhisa Kameyama and Mizuho Matsushita and Kanmei Rai and Ken Sato and Toshiro Yonei and Toshio Sato and Takuo Shibayama",
year = "2014",
doi = "10.1159/000357938",
language = "English",
volume = "7",
pages = "14--17",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "1",

}

TY - JOUR

T1 - Nab-paclitaxel in combination with carboplatin for a previously treated thymic carcinoma

AU - Makimoto, Go

AU - Fujiwara, Keiichi

AU - Watanabe, Hiromi

AU - Kameyama, Nobuhisa

AU - Matsushita, Mizuho

AU - Rai, Kanmei

AU - Sato, Ken

AU - Yonei, Toshiro

AU - Sato, Toshio

AU - Shibayama, Takuo

PY - 2014

Y1 - 2014

N2 - We present the case of a 40-year-old man with previously treated thymic carcinoma, complaining of gradually worsening back pain. Computed tomography scans of the chest showed multiple pleural disseminated nodules with a pleural effusion in the right thorax. The patient was treated with carboplatin on day 1 plus nab-paclitaxel on day 1 and 8 in cycles repeated every 4 weeks. Objective tumor shrinkage was observed after 4 cycles of this regimen. In addition, the elevated serum cytokeratin 19 fragment level decreased, and the patient's back pain was relieved without any analgesics. Although he experienced grade 4 neutropenia and granulocyte colony-stimulating factor (G-CSF) injection, the severity of thrombocytopenia and nonhematological toxicities such as reversible neuropathy did not exceed grade 1 during the treatment. To our knowledge, this is the first report to demonstrate the efficacy of combination chemotherapy consisting of carboplatin and nab-paclitaxel against thymic carcinoma. This case report suggests that nab-paclitaxel in combination with carboplatin can be a favorable chemotherapy regimen for advanced thymic carcinoma.

AB - We present the case of a 40-year-old man with previously treated thymic carcinoma, complaining of gradually worsening back pain. Computed tomography scans of the chest showed multiple pleural disseminated nodules with a pleural effusion in the right thorax. The patient was treated with carboplatin on day 1 plus nab-paclitaxel on day 1 and 8 in cycles repeated every 4 weeks. Objective tumor shrinkage was observed after 4 cycles of this regimen. In addition, the elevated serum cytokeratin 19 fragment level decreased, and the patient's back pain was relieved without any analgesics. Although he experienced grade 4 neutropenia and granulocyte colony-stimulating factor (G-CSF) injection, the severity of thrombocytopenia and nonhematological toxicities such as reversible neuropathy did not exceed grade 1 during the treatment. To our knowledge, this is the first report to demonstrate the efficacy of combination chemotherapy consisting of carboplatin and nab-paclitaxel against thymic carcinoma. This case report suggests that nab-paclitaxel in combination with carboplatin can be a favorable chemotherapy regimen for advanced thymic carcinoma.

KW - Carboplatin

KW - Chemotherapy

KW - nab-Paclitaxel

KW - Thymic carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84900472972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900472972&partnerID=8YFLogxK

U2 - 10.1159/000357938

DO - 10.1159/000357938

M3 - Article

VL - 7

SP - 14

EP - 17

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 1

ER -